The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
The Vaxxas high-density microarray patch (HD-MAP) is comprised of thousands of microscopic projections molded into a small patch. Each microprojection is ‘printed’ with a small dose of vaccine in a ...
A dengue virus vaccine candidate has passed an important milestone, with promising results in animal model testing providing hope to the 390 million people infected every year. The University of ...
Vaccine experts tend to be a serious bunch, but many are downright giddy about vaccine clinical trial results presented last week at a medical conference in Seattle. The actual vaccine isn't new — ...
A COVID-19 patch developed in Australia was found to be more effective than vaccines administered through a needle. UQ See more of our coverage in your search results. Add The New York Post on Google ...
- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...
- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results